Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

ClinicalTrials.gov ID: NCT02847559

Public ClinicalTrials.gov record NCT02847559. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 7, 2026, 6:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this research study is to determine the effects bevacizumab (the study drug) combined with Optune (the study device) tumor treatment field therapy has on meningiomas. Bevacizumab is considered investigational because the US Food and Drug Administration (FDA) has not approved its use for the treatment of meningiomas. The study drug is a medication that blocks the growth of new blood vessels. It is thought that the study drug may interfere with the growth of new blood vessels and therefore might stop tumor growth, and possibly shrink the tumor by keeping it from receiving nutrients and oxygen supplied by the blood vessels. Optune is also considered investigational because the US FDA has not approved its use for the treatment of meningiomas. Optune is a device that the patient will wear and use for at least 18 hours of each day. It delivers alternating electrical current to the patient's brain tumor and by doing so interrupts a process called mitosis. Mitosis needs to occur in order for cell division to occur and allows tumors to grow. By slowing this process, we hypothesize that meningioma growth may also be slowed.

Study identification

NCT ID: NCT02847559
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Northwestern University; Other
Enrollment: 27 participants

Conditions and interventions

Conditions

Interventions

Biological · Procedure · Device

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 31, 2016
Primary completion: Aug 31, 2026
Completion: Nov 30, 2026
Last update posted: Jun 26, 2025

2016 – 2026

United States locations

U.S. sites: 8
U.S. states: 6
U.S. cities: 8

Facility	City	State	ZIP	Site status
John Wayne Cancer Center at Providence St. John's Health Center	Santa Monica	California	90404	Completed
Miami Cancer Institute	Miami	Florida	33176	Completed
Piedmont Healthcare	Atlanta	Georgia	30309	Completed
Northwestern University	Chicago	Illinois	60611	Recruiting
Northwestern University- Lake Forest Hospital	Lake Forest	Illinois	60045	Active, not recruiting
Northwestern Medicine/ Cadence Health - CDH	Winfield	Illinois	60190	Recruiting
Vidant Medical Center, East Caroling University	Greenville	North Carolina	27834	Active, not recruiting
University of Pennsylvania	Philadelphia	Pennsylvania	19104	Active, not recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02847559, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 26, 2025 · Synced Sep 7, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02847559 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →